New research highlights broad health impacts of GLP-1 receptor agonists, including Alzheimer’s risk reduction and potential kidney damage.
A new study published in Nature Medicine reveals the complex health profile of GLP-1 receptor agonists (GLP-1RAs), a class of drugs initially designed to manage type 2 diabetes but increasingly prescribed for weight loss and investigated for other healthspan benefits. Researchers from Washington University in St. Louis analyzed health outcomes for 2.4 million patients over six years, identifying a mixture of significant benefits and concerning risks [1].
These findings come amidst a surge in the popularity of GLP-1RAs, such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro, which have transformed weight-loss treatment. The drugs have attracted widespread use, with some individuals obtaining them independently for aesthetic weight loss and other purported benefits rather than for medical purposes.
“Given the drugs’ newness and skyrocketing popularity, it is important to systematically examine their effects on all body systems – leaving no stone unturned – to understand what they do and what they don’t do,” said the study’s senior author, Ziyad Al-Aly, MD, a clinical epidemiologist and nephrologist.
“Our approach has allowed us to build a comprehensive atlas mapping the associations of GLP-1RA spanning all organ systems,” he added. “The study’s results provide insights into some known and previously unrecognized benefits and risks of GLP-1RA that may be useful to inform clinical care and guide research agendas [2].”
Longevity.Technology: These findings emphasize the need for nuanced discussions about GLP-1RAs, particularly as they gain traction beyond their intended audience of patients with diabetes and obesity. The combination of promising benefits, such as reduced Alzheimer’s risk, with serious risks, including kidney and pancreatic damage, necessitates balanced patient education and monitoring. With President Biden’s outgoing administration targeting Medicare negotiations to reduce drug costs, accessibility may increase further, emphasizing the importance of careful consideration for wider use.
This research serves as a reminder of the dual nature of pharmaceutical innovations – and the need to balance promise with caution. While GLP-1RAs represent a significant advancement in managing metabolic and neurodegenerative conditions, their widespread adoption must be tempered by vigilance regarding long-term risks; for both patients and prescribers, understanding the broader health implications of these drugs is essential to making informed decisions.
Evidence of broad benefits, including Alzheimer’s protection
The research found that GLP-1RAs significantly reduced the risk of 42 health conditions. Notably, patients who used these medications were 12% less likely to develop Alzheimer’s disease, aligning with emerging evidence that GLP-1RAs may have neuroprotective properties [1].
These drugs have also shown potential benefits for cardiovascular health, reducing major adverse cardiovascular events, and they may slow the progression of other neurodegenerative conditions such as Parkinson’s disease.
The study also highlighted improvements in metabolic and inflammatory markers, including reduced blood sugar levels, lower body weight and improved lipid profiles [1]. GLP-1RAs were linked to reduced risks of bacterial infections and some cancers associated with obesity. According to Al-Aly, these findings suggest the drugs’ potential for applications beyond diabetes and obesity, though careful consideration of their risks remains essential.
“Interestingly, GLP-1RA drugs act on receptors that are expressed in brain areas involved in impulse control, reward and addiction — potentially explaining their effectiveness in curbing appetite and addiction disorders,” he explained. “These drugs also reduce inflammation in the brain and result in weight loss; both these factors may improve brain health and explain the reduced risk of conditions like Alzheimer’s disease and dementia [2].”
The study also validated previous research indicating the drugs’ potential to reduce the risk of heart attacks, strokes and other cardiovascular issues [1].
While GLP-1RA drugs demonstrate efficacy across a broad range of health conditions, the associated benefits are relatively moderate, typically resulting in a 10 to 20 percent reduction for most outcomes [1]. For example, a 12% reduction in Alzheimer’s risk is comparable to lifestyle changes like regular physical activity or adherence to a Mediterranean diet, which are also known to provide modest yet meaningful benefits
“However, the modest effect does not negate the potential value of these drugs, especially for conditions where few effective treatment options exist, for example, dementia,” Al-Aly said. “This may also imply that these drugs are most beneficial when used in conjunction with other interventions, such as lifestyle changes or other medications [2].”
Risks include kidney and pancreatic complications
Despite the promising benefits, the study identified 19 conditions for which GLP-1RAs increased the risk [1]. The most notable were disorders affecting the pancreas and kidneys; an elevated risk of pancreatitis and acute kidney injury highlights the need for caution, especially in patients with preexisting vulnerabilities in these areas.
A surprising finding was the increased likelihood of arthritis, with an 11% higher risk observed among users of GLP-1RAs [1]. While weight loss might typically alleviate joint stress, the exact mechanisms driving the increased arthritis risk remain unclear; researchers speculate that systemic inflammatory changes or altered metabolic pathways induced by GLP-1RAs could play a role, and this is something that warrants further investigation.
Mechanisms of action provide insights into benefits and risks
GLP-1 drugs function through two main pathways: an indirect effect by reducing obesity and diabetes-related complications and a direct impact by enhancing the activity of glucagon-like peptide 1. This hormone plays diverse biological roles, influencing cardiovascular health, cognitive function and inflammation. However, these same systemic effects may contribute to unintended consequences, such as the slower gastric emptying associated with these drugs.
The study also raises questions about long-term use in non-diabetic populations. While GLP-1RAs have attracted attention for their potential in preventive medicine, the risks identified suggest that extensive clinical trials are needed before these drugs can be widely prescribed to healthier individuals.
“GLP-1RA drugs can have broad health benefits,” Al-Aly said. “However, they are not without risks. Our findings underscore the possibility for wider applications for these medications but also highlight important risks that should be carefully monitored in people taking these drugs [2].”
[1] https://www.nature.com/articles/s41591-024-03412-w
[2] https://medicine.washu.edu/news/study-identifies-benefits-risks-linked-to-popular-weight-loss-drugs/
